文献速递帕金森病与运动障碍认知障碍与痴呆

进行性核上性麻痹生存期的遗传决定因素:全基因组关联研究

Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study.
PubMed 文献 · Lancet Neurol · 2020-12-17

rs2242367与全血LRRK2及LINC02555、AC079630.4表达增加相关,提示LRRK2位点遗传变异与PSP生存相关。

要点

  • 该变异与全血LRRK2及lncRNA LINC02555表达增加相关。
  • LRRK2位点遗传变异可能通过lncRNA调控影响PSP生存。

核心结论

  • LRRK2位点的遗传变异与进行性核上性麻痹的生存期相关。
  • 该关联机制可能通过lncRNA调控LRRK2表达实现,提示与帕金森病存在遗传重叠。

研究设计与样本

  • 两阶段全基因组关联研究,第一阶段纳入1001例白种欧洲裔PSP患者,第二阶段纳入238例,汇总分析共1239例。
  • 生存期分析采用Cox比例风险模型,并利用eQTL数据库和共定位分析评估变异功能。

主要发现

  • eQTL数据库显示rs2242367与全血LRRK2及LINC02555、AC079630.4表达增加相关。

临床怎么用

  • LRRK2位点变异可能作为PSP生存预后的遗传标志物,但尚需进一步验证。
  • 该发现提示LRRK2调控可能成为PSP及相关tau蛋白病的疾病修饰治疗靶点。

局限性

  • 研究仅纳入白种欧洲裔人群,结果外推需谨慎。
  • 未检测到LRRK2的共定位信号,机制推断基于lncRNA调控的间接证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The genetic basis of variation in the progression of primary tauopathies has not been determined. We aimed to identify genetic determinants of survival in progressive supranuclear palsy (PSP). METHODS: In stage one of this two stage genome-wide association study (GWAS), we included individuals with PSP, diagnosed according to pathological and clinical criteria, from two separate cohorts: the 2011 PSP GWAS cohort, from brain banks based at the Mayo Clinic (Jacksonville, FL, USA) and in Munich (Germany), and the University College London PSP cohort, from brain banks and the PROSPECT study, a UK-wide longitudinal study of patients with atypical parkinsonian syndromes. Individuals were included if they had clinical data available on sex, age at motor symptom onset, disease duration (from motor symptom onset to death or to the date of censoring, Dec 1, 2019, if individuals were alive), and PSP phenotype (with reference to the 2017 Movement Disorder Society criteria). Genotype data were used to do a survival GWAS using a Cox proportional hazards model. In stage two, data from additional individuals from the Mayo Clinic brain bank, which were obtained after the 2011 PSP GWAS, were used for a pooled analysis. We assessed the expression quantitative trait loci (eQTL) profile of variants that passed genome-wide significance in our GWAS using the Functional Mapping and Annotation of GWAS platform, and did colocalisation analyses using the eQTLGen and PsychENCODE datasets. FINDINGS: Data were collected and analysed between Aug 1, 2016, and Feb 1, 2020. Data were available for 1001 individuals of white European ancestry with PSP in stage one. We found a genome-wide significant association with survival at chromosome 12 (lead single nucleotide polymorphism rs2242367, p=7·5 × 10-10, hazard ratio 1·42 [95% CI 1·22-1·67]). rs2242367 was associated with survival in the individuals added in stage two (n=238; p=0·049, 1·22 [1·00-1·48]) and in the pooled analysis of both stages (n=1239; p=1·3 × 10-10, 1·37 [1·25-1·51]). An eQTL database screen revealed that rs2242367 is associated with increased expression of LRRK2 and two long intergenic non-coding RNAs (lncRNAs), LINC02555 and AC079630.4, in whole blood. Although we did not detect a colocalisation signal for LRRK2, analysis of the PSP survival signal and eQTLs for LINC02555 in the eQTLGen blood dataset revealed a posterior probability of hypothesis 4 of 0·77, suggesting colocalisation due to a single shared causal variant. INTERPRETATION: Genetic variation at the LRRK2 locus was associated with survival in PSP. The mechanism of this association might be through a lncRNA-regulated effect on LRRK2 expression because LINC02555 has previously been shown to regulate LRRK2 expression. LRRK2 has been associated with sporadic and familial forms of Parkinson's disease, and our finding suggests a genetic overlap with PSP. Further functional studies will be important to assess the potential of LRRK2 modulation as a disease-modifying therapy for PSP and related tauopathies. FUNDING: PSP Association, CBD Solutions, Medical Research Council (UK).

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Jabbari E, Koga S, Valentino RR, et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurol. 2020. PMID: 33341150. doi:10.1016/S1474-4422(20)30394-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。